PMNNasdaqPharmaceutical PreparationsUS GAAP · USD

ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a U.S.-based biopharmaceutical company developing antibody therapies and therapeutic vaccines for neurodegenerative and other protein-misfolding diseases. Its research platform uses protein biology, physics, and supercomputing to identify disease-specific epitopes and design selective therapeutics and diagnostics, with a focus on Alzheimer’s disease, multiple system atrophy, and ALS.

Kysy yhtiöstä
Liikevoitto (EBIT)−40,2milj. USD
−138,7 %v/v
Nettotulos−39,7milj. USD
−1 529,3 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2021–2025

−50−40−30−20−100milj. USD2021: EBIT −8,3 milj. USD20212022: EBIT −23 milj. USD20222023: EBIT −14 milj. USD20232024: EBIT −17 milj. USD20242025: EBIT −40 milj. USD2025−40
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Antibody therapeutics40 %

Selective antibodies designed to target toxic misfolded proteins in neurodegenerative disease.

Therapeutic vaccines25 %

Vaccine candidates intended to generate immune responses against disease-specific protein conformations.

Discovery platform20 %

Computational and protein-biology tools used to identify disease-specific epitopes and candidates.

Diagnostics research10 %

Research efforts aimed at detecting toxic misfolded proteins for disease identification.

Collaborative licensing potential5 %

Potential future value from collaborations, licenses, or strategic transactions.

Asiakkaat

ProMIS does not sell commercial products today; its near-term counterparties are research partners, clinical investigators, regulators, and potential licensing or collaboration partners. If its programs advance, the eventual customers would be healthcare providers and patients in specialty neurology markets, but the business model is still centered on development-stage value creation rather than product sales.

Pharmaceutical collaboration partners

Potential partners that may license assets, fund development, or co-develop programs.

Clinical investigators and trial sites

Hospitals and research centers that enroll patients and generate clinical data for PMN310 and other programs.

Regulatory agencies

Agencies that review safety, biomarker, and efficacy data before any approval path.

Future neurology patients

Patients with Alzheimer’s disease, MSA, ALS, and other protein-misfolding disorders.

Strategia

ProMIS is focused on advancing its lead Alzheimer’s program PMN310 while continuing to build a pipeline across other protein-misfolding diseases. Its strategy depends on progressing preclinical and clinical work, refining biomarker and trial design, and securing external funding or partnerships to support development.

Advance PMN310 clinical developmentLyhyt aikaväli

The lead Alzheimer’s asset is central to the company’s value creation and partnering potential.

Broaden the pipeline across protein-misfolding diseasesKeskipitkä aikaväli

A broader portfolio can reduce single-asset dependence and expand partnering options.

Secure non-dilutive or dilutive fundingLyhyt aikaväli

Development-stage biotech requires ongoing capital to fund trials and regulatory work.

Maantiede

ProMIS is headquartered in the United States and its disclosures are presented in U.S. dollars. Its development work is organized around clinical and research activities rather than a manufacturing footprint, so geography mainly reflects where trials, collaborators, and capital markets are located.

Riskit

The company faces the typical risks of development-stage biotechnology, including clinical failure, regulatory setbacks, and the need for substantial external funding. Its disclosures also highlight going-concern uncertainty and a material weakness in internal control over financial reporting, both of which can affect execution and investor confidence.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Funding shortfall1Going-concern uncertainty2Clinical development failure3Internal control weakness4Regulatory and commercialization risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Funding shortfallVaikutus: KriittinenTodennäköisyys: Korkea

    The company has no revenue and needs additional capital to continue development and operations.

    KohdistuuEquityDebtATMCollaborations
  2. Going-concern uncertaintyVaikutus: KriittinenTodennäköisyys: Korkea

    Management disclosed substantial doubt about the ability to continue as a going concern.

    Kohdistuu: Near-term liquidity and operations

  3. Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea

    Drug candidates may not show sufficient safety or efficacy in preclinical or clinical studies.

    Kohdistuu: PMN310 and other pipeline assets

  4. Internal control weaknessVaikutus: KorkeaTodennäköisyys: Korkea

    A material weakness can delay reliable reporting and undermine investor confidence.

    Kohdistuu: Financial reporting and controls

  5. Regulatory and commercialization riskVaikutus: KorkeaTodennäköisyys: Korkea

    Even successful candidates require approvals, manufacturing readiness, and market access.

    Kohdistuu: Future product launch

Kirjanpito

Harkinnanvaraiset erät
Research and development accruals

Management must estimate unpaid clinical, CRO, and consultant costs, which can shift period expenses.

Vaikutus: Affects operating expenses and liabilities

Share-based compensation

Equity awards to employees and directors can be a significant non-cash expense in development-stage biotech.

Vaikutus: Affects operating loss and equity

Going-concern assessment

Cash runway judgments influence disclosure and investor assessment of solvency risk.

Vaikutus: Affects financial statement presentation and risk perception

Equity financing accounting

ATM sales, PIPEs, warrants, and pre-funded warrants require careful classification and issuance-cost treatment.

Vaikutus: Affects equity balances and financing cash flow presentation

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Prothena Corporation plc

PRTA · Pharmaceutical Preparations

BioVie Inc

BIVIW · Pharmaceutical Preparations

NeuroSense Therapeutics Ltd.

NRSNW · Pharmaceutical Preparations

Praxis Precision Medicines, Inc.

PRAX · Pharmaceutical Preparations

Jupiter Neurosciences, Inc

JUNS · Pharmaceutical Preparations

Assembly Biosciences, Inc

ASMB · Pharmaceutical Preparations

Päivitetty: 24.9.2026